tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AKBA Stock Latest News

Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics
RatingsStrategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics
9h ago
AKBA
Akebia price target lowered to $6 from $8 at H.C. Wainwright
PremiumThe Fly
Akebia price target lowered to $6 from $8 at H.C. Wainwright
9h ago
AKBA
Akebia Therapeutics Halts VALOR Trial for Vadadustat
PremiumCompany Announcements
Akebia Therapeutics Halts VALOR Trial for Vadadustat
2d ago
8K
AKBA
Akebia says not in alignment with FDA on path forward for VALOR clinical trial
PremiumThe Fly
Akebia says not in alignment with FDA on path forward for VALOR clinical trial
2d ago
AKBA
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Implications for Investors
PremiumCompany Announcements
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Implications for Investors
3d ago
AKBA
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications
PremiumCompany AnnouncementsAkebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications
3d ago
AKBA
Akebia’s Vadadustat Study: A Potential Game-Changer in Anemia Treatment for CKD
Premium
Company Announcements
Akebia’s Vadadustat Study: A Potential Game-Changer in Anemia Treatment for CKD
2M ago
AKBA
Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics
Premium
The Fly
Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics
2M ago
AKBA
Akebia Therapeutics Reports Record Revenue and Strategic Growth
PremiumCompany Announcements
Akebia Therapeutics Reports Record Revenue and Strategic Growth
3M ago
AKBA
Akebia Therapeutics Reports Strong Q2 2025 Growth
PremiumCompany Announcements
Akebia Therapeutics Reports Strong Q2 2025 Growth
3M ago
AKBA
Akebia reports Q2 EPS 0c vs (4c) last year
PremiumThe Fly
Akebia reports Q2 EPS 0c vs (4c) last year
3M ago
AKBA
Strategic Partnerships and Clinical Trials Propel Akebia Therapeutics’ Growth Potential
PremiumRatings
Strategic Partnerships and Clinical Trials Propel Akebia Therapeutics’ Growth Potential
3M ago
AKBA
Akebia Therapeutics (AKBA) Q2 Earnings Cheat Sheet
PremiumPre-EarningsAkebia Therapeutics (AKBA) Q2 Earnings Cheat Sheet
3M ago
AKBA
Akebia initiates post-marketing study to identify benefits of Vafseo
Premium
The Fly
Akebia initiates post-marketing study to identify benefits of Vafseo
3M ago
AKBA
Akebia Therapeutics Approves Stock Plan Amendment at Meeting
Premium
Company Announcements
Akebia Therapeutics Approves Stock Plan Amendment at Meeting
5M ago
8K
AKBA
International Paper, ImmunityBio, Agenus, Akebia, Apple: Trending by Analysts
PremiumWeekend Updates
International Paper, ImmunityBio, Agenus, Akebia, Apple: Trending by Analysts
5M ago
IP
AAPL
Akebia announces JASN published analysis from vadadustat phase 3 program
PremiumThe Fly
Akebia announces JASN published analysis from vadadustat phase 3 program
5M ago
AKBA
Buy Rating for Akebia Therapeutics Driven by VAFSEO’s Market Potential in CKD Anemia
PremiumRatings
Buy Rating for Akebia Therapeutics Driven by VAFSEO’s Market Potential in CKD Anemia
5M ago
AKBA
Akebia assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Akebia assumed with a Buy at H.C. Wainwright
5M ago
AKBA
Akebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial
PremiumRatingsAkebia Therapeutics’ Growth Potential Driven by Vafseo’s Market Expansion and Upcoming VALOR Trial
5M ago
AKBA
Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
Premium
Ratings
Akebia Therapeutics: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
6M ago
AKBA
Akebia Therapeutics Reports Strong Q1 2025 Performance
Premium
Company Announcements
Akebia Therapeutics Reports Strong Q1 2025 Performance
6M ago
AKBA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >